Loading data for IPHA — first visit, this takes a few seconds.
Innate Pharma S.A. (IPHA)
NasdaqGS: IPHA
· 实时价格 · USD
2.08
-0.03 (-1.42%)
收盘价： Sep 04, 2026, 3:59 PM
2.08
+0.09%
盘后: 5:40 PM
股价、关键数字和最新消息，都在这一页。
Innate Pharma S.A.（IPHA）股价、分析与数据
-1.42% (1D)
| 买价 | 2.19 |
| 市值 | 232M |
| 营收（TTM） | 9.01M |
| 净利润（TTM） | -49.2M |
| 0.88 | |
| -0.64 | |
| n/a | |
| -3.5 | |
| 市净率（TTM） | -7.73 |
| 市销率（TTM） | 25.80 |
| 财报日期 | Sep 17, 2026 |
| 卖价 | 2.21 |
| 成交量 | 8,979 |
| 20日均量 | 148,873 |
| 开盘价 | 2.10 |
| 前收盘价 | 2.11 |
| 日内区间 | 2.03 - 2.15 |
| 52周区间 | 1.17 - 2.71 |
| 分析师 | n/a |
| 目标价 | n/a |
| 分红 | n/a |
| 除息日 | n/a |
关于 IPHA
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a d...
公司完整简介财报意外
Innate Pharma S.A. 已于 Apr 3, 2022 发布季度财报：
- 营收为 n/a 低于预期 $0, ， NaN% 同比增长.
- 每股收益为 -0.16 超出预期 0.01, ， -Infinity% 同比下滑.
第 1 页，共 2 页